Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nevro (NYSE: NVRO), Nektar Therapeutics (NASDAQ: NKTR) and BeiGene Ltd (NASDAQ: BGNE).
Nevro (NYSE: NVRO)
In a report released today, Suraj Kalia from Northland Securities assigned a Hold rating to Nevro (NYSE: NVRO), with a price target of $80. The company’s shares opened today at $74.95.
Kalia observed:
“We have been given “anecdotes” of Nevro rep feedback to clinicians.”
According to TipRanks.com, Kalia is a 4-star analyst with an average return of 7.2% and a 60.0% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Obalon Therapeutics Inc, and Apollo Endosurgery Inc.
Currently, the analyst consensus on Nevro is Moderate Buy and the average price target is $94, representing a 25.4% upside.
In a report issued on May 8, Wells Fargo also downgraded the stock to Hold with a $84 price target.
See today’s analyst top recommended stocks >>
Nektar Therapeutics (NASDAQ: NKTR)
H.C. Wainwright analyst Debjit Chattopadhyay assigned a Buy rating to Nektar Therapeutics (NASDAQ: NKTR) today and set a price target of $125. The company’s shares opened today at $80.99.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.9% and a 50.3% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Jounce Therapeutics Inc.
Currently, the analyst consensus on Nektar Therapeutics is Strong Buy and the average price target is $107.63, representing a 32.9% upside.
In a report issued on May 11, Mizuho Securities also maintained a Buy rating on the stock with a $103 price target.
BeiGene Ltd (NASDAQ: BGNE)
Maxim Group analyst Jason McCarthy assigned a Buy rating to BeiGene Ltd (NASDAQ: BGNE) today and set a price target of $225. The company’s shares opened today at $182.76, close to its 52-week high of $194.70.
McCarthy noted:
“BeiGene announced that PARP inhibitor candidate pamiparib (BGB-290) has moved into a pivotal study for ovarian cancer in China. We are factoring in pamiparib for the Chinese ovarian cancer market into our model and raising our price target to $225, from $200.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 5.6% and a 45.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
BeiGene Ltd has an analyst consensus of Strong Buy, with a price target consensus of $179.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
